Extraintestinal Cancers in Inflammatory Bowel Disease: A Literature Review

Massano, A; Bertin, Luisa; Zingone, Fabiana; Buda, Andrea; Visaggi, Pierfrancesco; Bertani, Lorenzo; Bortoli, Nicola de; Fassan, Matteo; Scarpa, Marco; Ruffolo, Cesare; Angriman, Imerio; Bezzio, Cristina; Casini, Valentina; Ribaldone, Davide Giuseppe; Savarino, Edoardo; Barberio, Brigida

doi:10.3390/cancers15153824

Cited by 6 publications

(4 citation statements)

References 218 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Отдельные исследования демонстрируют ассоциации между ВЗК и РПЖ (ОР 1,43; р<0,01), особенно у пациентов с ВЗК и ПСХ (ОР 7,6; р<0,01) [98].…”

Section: внекишечный ракunclassified

“…Риск развития рака кожи принято считать более высоким для пациентов с ВЗК, получающих терапию тиопуринами [98]. Однако несколько популяционных исследований выявили связь между ВЗК и НМРК (ОР 1,5; р<0,01) [98].…”

Section: внекишечный ракunclassified

“…Между тем считается, что абсолютный риск развития гематологических злокачественных опухолей у пациентов с ВЗК остается относительно низким, а общая заболеваемость по-прежнему считается редкой [98]. Роль медикаментозной терапии, включая применение тиопуринов и ингибиторов ФНО-α как фактора риска развития гематологических злокачественных опухолей, остается неясной.…”

Section: внекишечный ракunclassified

“…Современные представления о пациентах с КРР, ассоциированным с ВЗК, включают следующие особенности: более частая встречаемость у мужчин (ОШ 1,10, 95% ДИ 1,05-1,16), значительно худшая общая выживаемость по сравнению с пациентами без ВЗК (ОР 1,33; 95% ДИ 1,20-1,47) [98], большая частота низкой дифференцировки (ОШ 2,02, 95% ДИ 1,6-2,6), муцинозных или перстневидноклеточных карцином (ОШ 2,43, 95% ДИ 1,3-4,4), синхронных опухолей (ОШ 3,2, 95% ДИ 2,3-4,5), правостороннего КРР (ОШ 1,6, 95% ДИ 1,1-2,1), меньшая частота радикальных резекций (ОШ 0,6, 95% ДИ 0,4-0,8). Пациенты с КРР, развившемся в результате ЯК, имеют более благоприятную общую выживаемость, чем при БК (ОР 0,79; 95% ДИ 0,7-0,9).…”

Section: колоректальный ракunclassified

See 3 more Smart Citations

Inflammatory bowel diseases: Transformation of representations. A review

Maev,

Bakulin,

Skalinskaya

et al. 2023

Terapevticheskii arkhiv

View full text Add to dashboard Cite

The global burden of inflammatory bowel disease (IBD) is currently significant and continues to grow due to the increasing prevalence of ulcerative colitis (UC) and Crohn's disease (CD), the increasing costs of diagnosis and treatment, and the high level of disability in patients with this disease. Categories, which leads to the search for risk factors and predictors of aggressive course and extraintestinal manifestations. According to the latest data, the prevalence of UC in Russia is 16.6 per 100 000 population, the annual registered increase is 11.3%; the prevalence of CD is 5.6 per 100 000 population, and the increase is 13.7%. In the Russian population of patients with IBD, the average age of disease onset is 35.3 years for UC and 31.2 years for CD. Moreover, in 89.3% of patients with UC, it took at least 2 years to verify the diagnosis, and in CD, within 2 years from the onset of clinical symptoms, the diagnosis was established in only 72.6% of patients. One of the dominant characteristics of IBD is its multisystem nature, which leads to the development of extraintestinal manifestations (ECM), which can be observed in 50–60% of patients, while up to 25% of patients with IBD have several EMC and the most common variants are joint lesions. A higher frequency of extraintestinal manifestations is observed in CD (up to 45% of patients), in female patients, in smokers and with a longer duration of the disease. To predict clinical remission, the level of fecal calprotectin and CRP, the need for glucocorticosteroids are important, to predict endoscopic remission – the level of fecal calprotectin, and to predict histological remission, an endoscopic Schroeder index value of ≤1 is important. The absolute risk of developing colorectal cancer in IBD remains relatively low, ranging from 1.1 to 5.4% after 20 years of disease. The main risk factors for IBD are total intestinal damage, high inflammatory activity, the stricturing phenotype of CD and the presence of primary sclerosing cholangitis.

show abstract

Section: внекишечный ракunclassified

Section: колоректальный ракunclassified

See 2 more Smart Citations

Inflammatory bowel diseases: Transformation of representations. A review

Maev,

Bakulin,

Skalinskaya

et al. 2023

Terapevticheskii arkhiv

View full text Add to dashboard Cite

show abstract

JAK Inhibitors: A Double‐Edged Sword in Immune‐Mediated Diseases Management

Bertin,

Savarino

2024

UEG Journal

View full text Add to dashboard Cite

JAK inhibitors are pivotal in treating immune‐mediated inflammatory diseases (IMIDs) like rheumatoid arthritis (RA) and inflammatory bowel disease. However, emerging safety concerns warrant careful evaluation. A recent analysis of the FDA Adverse Event Reporting System (FAERS) revealed that RA patients using JAK inhibitors face nearly double the risk of gastrointestinal perforations (GIPs) compared to those on biologics, particularly with concurrent steroid or NSAID use. Additionally, the FDA's ORAL Surveillance study linked tofacitinib with higher rates of cancer and cardiovascular events, prompting regulatory restrictions. These findings highlight the importance of balancing JAK inhibitors' therapeutic benefits with potential risks, emphasizing the need for patient‐centred risk assessment and vigilant monitoring to optimize outcomes.

show abstract